Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
Top Page
Artiva Biotherapeutics, Inc.
(NASDAQ:ARTV)
Select Model
Select Model
Rating:52Neutral
Price Target:
$5.50
▼(-24.55% Downside)
Action:ReiteratedDate:03/11/26
The score is held down primarily by weak financial performance—minimal revenue, widening losses, and persistent cash burn—despite modest leverage. Technicals are a key positive with a clear uptrend, though momentum appears overextended. Valuation signals are constrained by negative earnings and no dividend data, while recent executive/board additions provide a modest positive offset.
Positive Factors
Allogeneic NK cell platform
Artiva's allogeneic, off-the-shelf NK cell approach is a durable strategic advantage versus individualized autologous therapies: it supports scalable manufacturing, faster patient access and broader addressable markets. This structural model preserves margin and commercial optionality as programs advance.
Negative Factors
Persistent cash burn
Cash generation is weak and outflows are large and recurring, with 2025 showing an accelerated burn. Continued negative operating and free cash flow implies reliance on external capital, increasing dilution risk and constraining runway unless clinical or revenue milestones alter funding needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Allogeneic NK cell platform
Artiva's allogeneic, off-the-shelf NK cell approach is a durable strategic advantage versus individualized autologous therapies: it supports scalable manufacturing, faster patient access and broader addressable markets. This structural model preserves margin and commercial optionality as programs advance.
Read all positive factors
Artiva Biotherapeutics, Inc. (ARTV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$180.18M
Dividend YieldN/A
Average Volume (3M)176.85K
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue Growth-100.00%
EPS Growth-17.10%
CountryUS
Employees96
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding24,716,673
10 Day Avg. Volume132,684
30 Day Avg. Volume176,850
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-112.28
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$17.00Price Target Upside133.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.39
Revenue Forecast (FY)N/A
Artiva Biotherapeutics, Inc. Business Overview & Revenue Model
Company Description
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an of...
How the Company Makes Money
null...
Artiva Biotherapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 251.00K | 33.49M | 4.93M | 2.00M |
| Gross Profit | -2.60M | 251.00K | 33.49M | 4.93M | 2.00M |
| EBITDA | -88.01M | -64.85M | -28.41M | -58.67M | -71.58M |
| Net Income | -83.86M | -58.49M | -27.70M | -58.39M | -71.83M |
Balance Sheet | |||||
| Total Assets | 130.94M | 209.58M | 105.11M | 133.05M | 169.93M |
| Cash, Cash Equivalents and Short-Term Investments | 108.01M | 185.43M | 76.97M | 102.53M | 160.92M |
| Total Debt | 10.94M | 14.35M | 16.91M | 19.45M | 1.74M |
| Total Liabilities | 20.97M | 22.94M | 267.13M | 273.75M | 258.78M |
| Stockholders Equity | 109.97M | 186.64M | -162.01M | -140.70M | -88.86M |
Cash Flow | |||||
| Free Cash Flow | -79.34M | -55.67M | -50.69M | -57.13M | -17.03M |
| Operating Cash Flow | -76.75M | -55.03M | -47.43M | -50.83M | -15.30M |
| Investing Cash Flow | 63.41M | -120.46M | -25.98M | -6.30M | -1.72M |
| Financing Cash Flow | 9.00K | 162.23M | 24.39M | -1.26M | 152.75M |
Artiva Biotherapeutics, Inc. Technical Analysis
Positive
7.29
Price Trends
5.16
Positive
4.59
Positive
3.74
Positive
Market Momentum
0.35
Negative
69.27
Neutral
84.48
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTV, the sentiment is Positive. The current price of 7.29 is above the 20-day moving average (MA) of 5.99, above the 50-day MA of 5.16, and above the 200-day MA of 3.74, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 69.27 is Neutral, neither overbought nor oversold. The STOCH value of 84.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARTV.
Artiva Biotherapeutics, Inc. Risk Analysis
Artiva Biotherapeutics, Inc. disclosed 91 risk factors in its most recent earnings report. Artiva Biotherapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Artiva Biotherapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $180.18M | -1.26 | -60.22% | ― | -100.00% | -17.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $19.16M | -0.46 | -191.12% | ― | ― | -24.38% | |
49 Neutral | $81.11M | -0.79 | -69.56% | ― | ― | 14.19% | |
45 Neutral | $66.22M | -0.50 | -82.96% | ― | ― | 25.89% | |
45 Neutral | $35.36M | -3.48 | -88.89% | ― | 56.52% | 75.22% |
* Healthcare Sector Average
ARTV
Artiva Biotherapeutics, Inc.
7.29
5.37
279.69%
ACET
Adicet Bio
6.90
-2.70
-28.12%
ABVC
ABVC BioPharma
1.39
0.50
56.18%
JSPR
Jasper Therapeutics
0.68
-2.79
-80.29%
PLRX
Pliant Therapeutics
1.31
0.08
6.94%
Artiva Biotherapeutics, Inc. Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer
Positive
Feb 24, 2026
Artiva Biotherapeutics announced on February 24, 2026 that its board appointed veteran finance executive Thad Huston as chief financial officer, effective February 18, 2026, making him the company’s principal financial and accounting officer...
Executive/Board Changes
Artiva Biotherapeutics Adds Veteran Executive Elaine Sorg to Board
Positive
Feb 19, 2026
On February 18, 2026, Artiva Biotherapeutics appointed veteran pharmaceutical executive Elaine Sorg as a Class I director, with her term running until the company’s 2028 annual shareholder meeting. The decision followed a recommendation from...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.